All hands on deck: Malaria control urgently needs workable public-private-philanthropic partnerships (PPPP)

• DOI: 10.1371/journal.pgph.0001891
• Publication Date: 2023-04-25T17:59:42Z
• Authors: Kolawole Maxwell; Elisabeth G. Ches...; Perpetua Uhomoibhi; Christian Kompaoré; Jimmy Opigo; James K. Tibenderana
• Keywords: Opinion; Public aspects of medicine; RA1-1270

Between 2000 and 2015, great progress was made to drive down malaria, with incidence mortality rates from the disease falling by 27% 50% respectively [1].This a result of effective programming increased global attention funding for disease.However, since 2015 rate has fallen less than 2% gap continued widen US$ 2.6 billion in 2019 3.8 2021 [1].The COVID-19 pandemic further pushed back progress, especially sub-Saharan Africa where malaria cases rose over 7% between while remained stagnant [1].For community tip balance towards eradication an all hands on deck approach must be taken.We propose creating conditions that allow public-private-philanthropic (PPP) partnerships i.e. collaborations public, private for-profit, non-profit health subsectors, help sustain Africa.The sector health, even services, is well developed Sub-Saharan Africa; countries such as Nigeria Uganda, half citizens receive treatment [2,3].A large number also purchase commodities vendors pharmacies [2,3].However, largely unregulated, type, quality, affordability services vary.Because available products are often determined customer demand, patients may not always have access rapid diagnostic tests (RDTs) or quality-assured (QA) medicines which seen unnecessary additional expense.In public RDT coverage average 64% whereas formal it just 48% [1].A lack testing availability can lead prescription use antimalarials, presumptive diagnosis incorrect up 90% time [4], increases risk antimalarial drug resistance.Attempts been improve quality through public-private Affordable Medicines Facility Malaria (AMF-m) transitioned Private Sector Co-payment Mechanism (PSCM) Unitaid's project.The AMF-m significantly percentage for-profit outlets QA Artemisinin-based combination therapies (ACTs) five (Ghana 25% 83%, Kenya 21% 60%, 53% Tanzania 11% 66%) [5].However studies needed assess long-term sustainability results partnership ended 2017.Similarly,